FDA Accepts Jazz Pharmaceuticals’ NDA for Solriamfetol Treatment in Patients with Narcolepsy and Sleep Apnea

On March 2, Jazz Pharmaceuticals plc (JAZZ) announced that the FDA has accepted the company’s filing of a New Drug Application (NDA) with standard review for market approval of Solriamfetol. The drug is an investigational medicine used for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea (OSA). The company hopes to have an FDA decision by December 20.


Sonal detected the event and sent an alert to subscribers at 8:30 am. The next trade was at 9:05 am for $141. The market opened for regular market trading at $140.38. The stock closed higher on the day of the announcement and continued to rise over the next five trading sessions. Jazz Pharmaceuticals closed at $152.31 on March 9 for a gain of 8% in the week after the announcement.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!